Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

NCT02451111 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

190

Enrollment

OTHER

Sponsor class

Stopped The premature termination is based on the decision by the SAKK board on November 14, 2020 due to the lack of further financial support for the follow up period.

Conditions

Follicular Lymphoma

Interventions

DRUG: Ibrutinib
DRUG: Rituximab

Sponsor

Swiss Cancer Institute

Collaborators

[object Object]